Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q2 FY21 results · Jul–Sep 2020
Lincoln Pharmaceuticals reported revenue from operations of ₹122.29 crore (up 10.6% from Q2 FY20) and net profit of ₹20.20 crore (up 12.3% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a standalone basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 122.29 | 110.60 | +10.6% | 101.03 | +21.0% |
| Other income | 1.22 | 2.88 | −57.6% | 1.97 | −38.2% |
| Total income | 123.51 | 113.47 | +8.8% | 103.01 | +19.9% |
| Profit before tax | 27.39 | 23.62 | +16.0% | 20.67 | +32.5% |
| Net profit for the period | 20.20 | 17.99 | +12.3% | 14.99 | +34.7% |
| EPS, basic (₹) | 10.10 | 8.99 | +12.3% | 7.50 | +34.7% |
| Net margin (%) | 16.5 | 16.3 | 14.8 |
Standalone
- Filed with BSE
- 03 Nov 2020, 18:45 IST
- Board meeting
- 03 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE